Generics 44

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Deferasirox manufacturers

44 products found

Filters

deferasirox

Tablets, orally disintegrating (ODT) 125 mg, 250 mg, 500 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Available for
Licensing with supply, Technology transfer
Comments
Ref: Exjade ®
Manufacturer #337
A pharmaceutical manufacturer based in the EU that has been active in 90+ countries selling its products in the EU, Africa, North America, Middle East, and Asia for 30+ years. Key production lines are Rx and OTC. Main therapeutic areas include diabetes, CNS, and dermatology. The company's production lines are GMP-compliant. The company possesses branches in the Middle East and Asia.

Manufacturer usually replies in 5 days

deferasirox

Tablets 90 mg, 180 mg, 360 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
MAs for sale
Bulgaria , Malta , Netherlands
Comments
DCP approved
Manufacturer #276
This company is a global manufacturer and distributor of high-quality generic medicines, with a mission to make these medicines accessible to patients worldwide. It operates in several regions, including Europe and Latin America, and emphasizes strong partnerships within the pharmaceutical industry to expand its reach. The company is committed to sustainability and transparency, following Environmental, Social, and Governance (ESG) principles. They regularly engage in major industry events, highlighting their dedication to networking and maintaining a leading position in the market for generic medications.

Manufacturer usually replies in 6 days

deferasirox

Tablets, orally disintegrating (ODT) 125 mg, 250 mg, 500 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Algeria , Bahrain , Egypt , Iran , Iraq , Israel , Kuwait , Morocco , Oman , Saudi Arabia , Tunisia , United Arab Emirates , Vietnam
Available for
Licensing with supply, Technology transfer
Manufacturer #260
Pharmaceutical manufacturer operating in the EU for 50+ years. Activities include scientific development, manufacturing, out-licensing, marketing, and distribution of high-quality generic medicines. The company owns several production facilities that all comply with EU GMP requirements. Key dosage forms include conventional solids, cytostatic injectables, and cytostatic orals. The company holds an in-house R&D and Intellectual property business unit, as well as a regulatory affairs team that prepares CTD dossiers and maintains direct contact with regulatory agencies worldwide. The portfolio includes more than three thousand MA sets approved in the EU while hundreds of MA are in progress. Key therapy lines are cardiovascular, CNS, diabetes, immunology, oncology, and more. The company is active in nearly 100 countries worldwide, selling its products in Africa, Asia, Australia, Europe, LATAM, and the Middle East.

Manufacturer usually replies in 12 days

Want to see all 44 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Deferasirox Manufacturers

Deferasirox is an iron chelator belonging to a class of medications called Iron-Chelating agents. Deferasirox is the first oral medication approved by FDA for chronic iron overload in patients receiving blood transfusion for a prolonged use and this medication is also used to treat high levels of iron in people with certain blood disorders who actually do not require blood transfusion. Blood transfusion is often needed in few types of blood diseases such as anemia, sickle cell disease, which leads to additional iron that may build up in the body and cause problems such as diabetes, liver disease, heart failure etc, and deferasirox is used to eliminate the additional iron from the bloodstream and reduces the risk of these diseases.

Before using deferasirox, the risk of taking the drug must be weighed against the benefits it provides. It is always recommended to consult a physician before taking deferasirox as this medication may interact with other drugs or health problems.

Deferasirox is advised as a prescription product as well as generic prescription product. Manufacturers market deferasirox under the Brand name of Exjade, Jadenu. Deferasirox is available in a dosage form of tablet, granules, tablet for suspension in dosage strengths of 90 mg, 125 mg, 250 mg, 500 mg which is taken by mouth once daily on an empty stomach half an hour before meals. Deferasirox tablets are supplied as round, white, film coated tablets imprinted with the first letter of brand name and strength on one side and manufacturer name on the other side in a bottle of 30 tablets.

Deferasirox therapy should be considered only when a patient has proof of iron overload over a long-term blood transfusion, the recommended initial dose of deferasirox in transfusional iron overload patients with 2 years of age and older with estimated glomerular filtrate rate greater than 60 mL/min/1.73 m2 is 20 mg per kg body weight given orally once daily. The recommended initial dose of deferasirox in iron overload in non-transfusion-dependent thalassemia syndromes in patients with eGFR greater than 60 mL/min/1.73 m2 is 10 mg per kg body weight given orally once daily. Deferasirox Tablets are recommended to be stored at 25° C (77° F), in well closed containers with excursions permitted to 15° C to 30° C (59° F to 86° F) with protection from moisture.

Wholesale Price of Deferasirox

The wholesale price for 30 units of 90 mg deferasirox oral tablet is $ 966 with per unit cost comes at $ 32.21 The cost for deferasirox 180 mg oral tablet is around $ 1922 for a supply of 30 tablets with per unit cost available for as low as $ 64 The cost for deferasirox oral granule for reconstitution 90 mg is around $ 914 for a supply of 30 tablets with per unit cost available for as low as $ 30.47

Deferasirox - Mechanism of Action

Deferasirox works by binding to iron in the bloodstream by forming a stable complex which is eliminated through kidneys.

Finding Deferasirox Manufacturers and Suppliers

To find a trustful partner in any business is one of the tedious tasks and to overcome that challenge and to make one’s work / life easy in finding the trustful and suitable manufacturer and supplier of Deferasirox one can visit the Pipelinepharma website which helps the buyer in finding the dependable manufacturers and suppliers of Deferasirox. Pipelinepharma, which is a business-to-business (B2B) licensing marketplace for pharmaceutical products, quickly connects owner with the buyer for the business advancement. One can filter the product names in unified search engine by its country, category, therapeutic area, forms, dossier and its status, regulatory filings, approvals, and many more.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation